周洲副教授(博士生导师)
单位：四川大学华西药学院药剂系
通讯地址：成都市人民南路三段17号四川大学华西药学院
E-mail: zhou_zhou610@163.com
简历
2005-2009 中山大学药学院，获理学学士学位
2009-2015 四川大学华西药学院，获药剂学博士学位
2015- 四川大学华西药学院药剂系任讲师、副教授
2018-2019 美国犹他大学药学院访问学者
研究方向
自身免疫性疾病的靶向给药系统的构建及其作用机制研究
主要研究课题
1.国家自然科学基金委员会，面上项目，82373819，2024至2027，主持。
2.国家自然科学基金委员会，青年基金项目，81603042，2017至2019，主持。
3.四川省科技厅，自然科学基金面上项目，2025ZNSFSC0723，2025至2026，主持。
4.四川省科技厅，重点研发项目，2018SZ0032，2018至2019，主持。
5.四川大学青年教师启动基金，2016SCU11008，2016至2017，主持。
近年代表性论著
1.Kai Huang, Hui-Zhi Liu, Yuan Liu, Jia-Yan Lyu, Qing-Yi Zhang, Zi-Yuan Feng, Zi-Lin Wang, Hui Dong, Rong Nie, Yi-Wen Zhang, Yue-Qi Zhang, Yi Zeng, Hui-Qi Xie*,Zhou Zhou*，Bin Shen*. Hybrid exosomal nanomotors convert pathological ROS into transport-driving cues to enhance cartilage accumulation in osteoarthritis.Nat Commun(2026).https://doi.org/10.1038/s41467-026-76949-8.
2.Zhihua Liu, Jiahui Wu, Jiayan Lyu,Zhou Zhou*, Yuan Huang*. Modulating macrophage efferocytosis: Drug delivery strategies for enhancement, mimicry, and inhibition.Acta Pharmaceutica Sinica B, 2026, https://doi.org/10.1016/j.apsb.2026.07.051.
3.Minyi Huang, Huizhi Liu, Jiahui Wu, Jing Tao, Yating Wang, Lian Li, Yuan Huang, Zhou Zhou*. Engineered Nanosponge Platform Corrects TLR7-Related Efferocytosis and Platelet-Activation for Treatment of Different Systemic Lupus Erythematosus Stages.Advanced Functional Materials, 2026, 36, e14092.
4.Huizhi Liu, Minyi Huang, Jiayan Lyu, Jing Tao, Yunshi Li, Lian Li, Yuan Huang,Zhou Zhou*. Enhance Efferocytosis and Block the Macrophages-Platelets Feedback Loop for Targeted Treatment of Psoriasis.ACS Nano, 2025, 19, 12, 11774-11791.
5.Zhanghan Wu†, Jing Tao†, Yuan Yao, Yuan Huang, Lian Li, Dan Cao* andZhou Zhou*. A nano-system combines mitochondrial damage with microtubule stabilization for cancer metastasis suppression.Journal of Materials Chemistry B, 2025,13, 14718-14733.
6.Jing Tao, Yuan Yao, Minyi Huang, Jiahui Wu, Jiayan Lyu, Qiuyi Li, Lian Li, Yuan Huang,Zhou Zhou*.A nano-platform combats the “attack” and “defense” of cytoskeleton to block cascading tumor metastasis.Journal of Controlled Release,2024, 367: 572-586.
7.Jiayan Lyu, Huizhi Liu, Liqiang Chen, Chendong Liu, Jing Tao, Yuan Yao, Lian Li, Yuan Huang,Zhou Zhou*.In situ hydrogel enhances non-efferocytic phagocytosis for post-surgical tumor treatment. Journal of Controlled Release, 2023,363, 402-414.
8.Yuan Yao, Jing Tao, Jiayan Lyu, Cheng Chen, Yuan Huang, andZhou Zhou*.Enhance Mitochondrial Damage by Nuclear Export Inhibition toSuppress Tumor Growth and Metastasis with Increased Antitumor Properties of Macrophages.ACS Appl. Mater. Interfaces,2023, 15, 20774-20787.
9.Chaohui Luo,Minglu Zhou,Cheng Chen,Shujie Li,Qiuyi Li,Yuan Huang,Zhou Zhou*.Aliposome-based combination strategy using doxorubicin and a PI3K inhibitor efficiently inhibits pre-metastatic initiation by acting on both tumor cells and tumor-associated macrophages.Nanoscale, 2022, 14(12): 4573-4587.
10.Jiatao Yang, Qiuyi Li, Rui Zhou, Minglu Zhou, Xi Lin, Yucheng Xiang, Dandan Xie, Yuan Huang andZhou Zhou*. Combination of mitochondria targeting doxorubicin with Bcl-2 function-converting peptide NuBCP-9 for synergistic breast cancer metastasis inhibition.Journal of Materials Chemistry B, 2021, 9(5): 1336-1350.
11.Qiuyi Li,Jiatao Yang, Cheng Chen, Xi Lin, Minglu Zhou,Zhou Zhou*, Yuan Huang*. A novel mitochondrial targeted hybrid peptide modified HPMA copolymers for breast cancer metastasis suppression.Journal of Controlled Release,2020, 325: 38-51.
